Q-omics provides the consensus-scored IKZF3 profile across patient tissues and cancer cell-line models. IKZF3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IKZF3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, IKZF3 RNA expression shows 19,262 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where IKZF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IKZF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IKZF3 survival associations across molecular data types. IKZF3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IKZF3 RNA expression–survival associations across cancer types. High IKZF3 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, LUAD, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IKZF3 RNA expression.
This table summarizes IKZF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IKZF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IKZF3 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, THCA, STAD and BLCA. The KIRC box plot shows higher IKZF3 RNA expression in tumor versus normal tissue (log2 FC = +1.770, t-test p < 0.001).
This table shows molecular features associated with IKZF3 in patient tissues and cancer cell lines. In patient samples, IKZF3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IKZF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
